Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Early-stage, Novel and Compelling Dual-functional Drug for Improved Treatment of Resistant Colon and Lung Cancers and Chronic Myelogenous (or Myeloid) Leukemia (CML).
Pharmalicensing USA flag USA
Abstract ID:
A compelling early stage dual functional treatment for resistant colon and lung cancers chronic myelogenous (or myeloid) leukemia with higher efficacy, lower toxicity, and greater ability to combat drug resistance than other clinically available drugs....
Contact Joel Edelson
Participants
You
Email me a copy of this message

Our client’s lead candidate is a novel targeted and dual-functional analog with significantly higher efficacy and markedly lower toxicity when compared to established first line treatments such as Irinotecan, Topotecan Etoposide, and Imatinib and targeted therapy drug called tyrosine kinase inhibitor (TKI) in the treatment of resistant colon and lung cancers, and CML. It produced 37.5% cure rate in mice bearing human CML xenografts that were highly resistant to Imatinib.

The lead candidate has proven to be very effective at killing human colon and lung cancer cells in vitro while also being remarkably effective at inhibiting the growth of human colon cancer xenografts. Perhaps most importantly, its toxicity is extremely low with a maximum tolerated dose (MTD) of 300 mg/kg (i.p.) and 180 mg/kg (i.v.) in mice, respectively. Its toxicity is much lower than that of Topotecan (MTD: 15 mg/kg, i.v. in mice), Etoposide (LD50: 15.07 mg/kg, i.v. in mice), Irinotecan (LD50: 132 mg/kg, i.v. in mice and other known clinically available drugs.

GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated Nov 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
CORPORATION
Company Logo